Artelo Biosciences, Inc. (NASDAQ:ARTL – Get Free Report) shares were down 1.8% during mid-day trading on Wednesday . The company traded as low as $1.0401 and last traded at $1.10. 689,856 shares were traded during trading, an increase of 162% from the average session volume of 262,956 shares. The stock had previously closed at $1.12.
Analyst Ratings Changes
Several analysts have recently commented on ARTL shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Wednesday, June 24th. Wall Street Zen raised Artelo Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Artelo Biosciences presently has an average rating of “Reduce” and a consensus target price of $54.00.
Read Our Latest Research Report on Artelo Biosciences
Artelo Biosciences Stock Performance
Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($4.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($3.22).
About Artelo Biosciences
Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.
The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.
Featured Stories
- Five stocks we like better than Artelo Biosciences
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
